{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:49:31Z","timestamp":1791348571665,"version":"4.3.1"},"reference-count":122,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3293,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1038\/sj.ki.5001835","type":"journal-article","created":{"date-parts":[[2006,10,4]],"date-time":"2006-10-04T15:23:47Z","timestamp":1159975427000},"page":"1905-1913","source":"Crossref","is-referenced-by-count":172,"title":["Beta blockers in the management of chronic kidney disease"],"prefix":"10.1016","volume":"70","author":[{"given":"G.L.","family":"Bakris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/sj.ki.5001835_bb0010","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/01.HYP.0000047205.52509.8A","article-title":"Neural control of the kidney: past, present, and future","volume":"41","author":"DiBona","year":"2003","journal-title":"Hypertension"},{"key":"10.1038\/sj.ki.5001835_bb0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s11906-002-0016-3","article-title":"Neurogenic factors in renal hypertension","volume":"4","author":"Campese","year":"2002","journal-title":"Curr Hypertens Rep"},{"key":"10.1038\/sj.ki.5001835_bb0020","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ki.1997.103","article-title":"Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure","volume":"51","author":"Ye","year":"1997","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001835_bb0025","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.HYP.25.4.878","article-title":"Renal afferent denervation prevents hypertension in rats with chronic renal failure","volume":"25","author":"Campese","year":"1995","journal-title":"Hypertension"},{"key":"10.1038\/sj.ki.5001835_bb0030","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0895-7061(02)02959-X","article-title":"Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity","volume":"15","author":"Ye","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1038\/sj.ki.5001835_bb0035","first-page":"189","article-title":"Effects of carvedilol and BL-443 on kidney of rats with cyclosporine nephropathy","volume":"21","author":"Salplachta","year":"2002","journal-title":"Gen Physiol Biophys"},{"key":"10.1038\/sj.ki.5001835_bb0040","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/oxfordjournals.ndt.a027447","article-title":"Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure","volume":"11","author":"Amann","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001835_bb0045","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1681\/ASN.V123602","article-title":"Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy?","volume":"12","author":"Strojek","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/sj.ki.5001835_bb0050","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1097\/00004872-200309000-00021","article-title":"Moxonidine treatment of hypertensive patients with advanced renal failure","volume":"21","author":"Vonend","year":"2003","journal-title":"J Hypertens"},{"key":"10.1038\/sj.ki.5001835_bb0055","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5414\/CNP63446","article-title":"Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy","volume":"63","author":"Jovanovic","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1038\/sj.ki.5001835_bb0060","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/ndt\/15.10.1493","article-title":"Microvascular disease \u2013 the Cinderella of uraemic heart disease","volume":"15","author":"Amann","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001835_bb0065","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/sj.ki.5001835_bb0070","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1681\/ASN.V1181469","article-title":"Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats","volume":"11","author":"Amann","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/sj.ki.5001835_bb0075","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1093\/ndt\/12.12.2497","article-title":"Nephrologists neglect administration of betablockers to dialysed diabetic patients","volume":"12","author":"Zuanetti","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001835_bb0080","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/ndt\/gfh288","article-title":"The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey","volume":"19","author":"Paoletti","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001835_bb0085","first-page":"H846","article-title":"Reduced chronotropic responsiveness of the heart in experimental uremia","volume":"250","author":"Mann","year":"1986","journal-title":"Am J Physiol"},{"key":"10.1038\/sj.ki.5001835_bb0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1681\/ASN.V131117","article-title":"Cardiac beta-adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia","volume":"13","author":"Leineweber","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/sj.ki.5001835_bb0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ki.1982.4","article-title":"Diminished vascular response to noradrenaline in experimental chronic uremia","volume":"21","author":"Rascher","year":"1982","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001835_bb0100","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJM199212313272704","article-title":"Sympathetic overactivity in patients with chronic renal failure","volume":"327","author":"Converse","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001835_bb0105","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJM199904293401704","article-title":"Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure","volume":"340","author":"Ligtenberg","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001835_bb0110","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1681\/ASN.V12112427","article-title":"Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension","volume":"12","author":"Klein","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/sj.ki.5001835_bb0115","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1161\/01.CIR.0000034043.16664.96","article-title":"Sympathetic nerve activity in end-stage renal disease","volume":"106","author":"Hausberg","year":"2002","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5001835_bb0120","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/ajkd.1998.v32.pm9820462","article-title":"On the epidemic of cardiovascular disease in patients with chronic renal disease and progressive renal failure: a first step to improve the outcomes","volume":"32","author":"Eknoyan","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001835_bb0125","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1001\/archinte.164.22.2465","article-title":"Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality","volume":"164","author":"Abbott","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1038\/sj.ki.5001835_bb0130","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1038\/sj.ki.5001835_bb0135","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.CIR.0000134791.68010.FA","volume":"110","author":"Antman","year":"2004","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5001835_bb0140","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1046\/j.1523-1755.2002.00636.x","article-title":"Blood pressure and long-term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study","volume":"62","author":"Foley","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001835_bb0145","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.0894-0959.2004.17329.x","article-title":"Drug therapy for hypertension in hemodialysis patients","volume":"17","author":"Horl","year":"2004","journal-title":"Semin Dial"},{"key":"10.1038\/sj.ki.5001835_bb0150","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0895-7061(03)00968-3","article-title":"Role for beta-blockers in the management of diabetic kidney disease","volume":"16","author":"Bakris","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1038\/sj.ki.5001835_bb0155","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1046\/j.1523-1755.2002.00638.x","article-title":"Incident acute coronary syndromes in chronic dialysis patients in the United States","volume":"62","author":"Trespalacios","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001835_bb0160","doi-asserted-by":"crossref","first-page":"563","DOI":"10.7326\/0003-4819-137-7-200210010-00007","article-title":"Acute myocardial infarction and renal dysfunction: a high-risk combination","volume":"137","author":"Wright","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1038\/sj.ki.5001835_bb0165","first-page":"89S","article-title":"Clinical pharmacology of labetalol","volume":"8","author":"Richards","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/sj.ki.5001835_bb0170","series-title":"Inderal\u00ae (propranolol hydrochloride) tablets (prescribing information)","year":"2005"},{"key":"10.1038\/sj.ki.5001835_bb0175","series-title":"Tenormin\u00ae (atenolol) tablets (prescribing information)","year":"2000"},{"issue":"Suppl 1","key":"10.1038\/sj.ki.5001835_bb0180","doi-asserted-by":"crossref","first-page":"I41","DOI":"10.1007\/s003950070008","article-title":"Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?","volume":"95","author":"Hjalmarson","year":"2000","journal-title":"Basic Res Cardiol"},{"key":"10.1038\/sj.ki.5001835_bb0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/clpt.1981.127","article-title":"Effects of labetalol and methyldopa on renal function","volume":"30","author":"Cruz","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/sj.ki.5001835_bb0190","first-page":"53","article-title":"\u03b2-Blockers and the kidney: implications for renal function and renin release","volume":"28","author":"Epstein","year":"1985","journal-title":"The Physiologist"},{"key":"10.1038\/sj.ki.5001835_bb0195","doi-asserted-by":"crossref","first-page":"955","DOI":"10.7326\/0003-4819-126-12-199706150-00004","article-title":"Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial","volume":"126","author":"Giugliano","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1038\/sj.ki.5001835_bb0200","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00004872-199604000-00012","article-title":"Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study","volume":"14","author":"Jacob","year":"1996","journal-title":"J Hypertens"},{"key":"10.1038\/sj.ki.5001835_bb0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.0954-6820.1985.tb08823.x","article-title":"Effects of long-term therapy with labetalol on lipoprotein metabolism in patients with mild hypertension","volume":"218","author":"Hylander","year":"1985","journal-title":"Acta Med Scand"},{"key":"10.1038\/sj.ki.5001835_bb0210","doi-asserted-by":"crossref","first-page":"123S","DOI":"10.1111\/j.1365-2125.1982.tb01900.x","article-title":"Renal haemodynamics after chronic treatment with labetalol and propranolol","volume":"13","author":"Malini","year":"1982","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/sj.ki.5001835_bb0215","series-title":"Drug Facts and Comparisons 2006","year":"2005"},{"key":"10.1038\/sj.ki.5001835_bb0220","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0002-8703(82)90127-2","article-title":"Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents","volume":"104","author":"Meier","year":"1982","journal-title":"Am Heart J"},{"issue":"Suppl 2","key":"10.1038\/sj.ki.5001835_bb0225","first-page":"28","article-title":"Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and\/or renal clearance","volume":"8","author":"Borchard","year":"1990","journal-title":"Clin Physiol Biochem"},{"key":"10.1038\/sj.ki.5001835_bb0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0033-0620(98)80030-3","article-title":"Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice","volume":"41","author":"Packer","year":"1998","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1038\/sj.ki.5001835_bb0235","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-7061(98)00141-1","article-title":"Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?","volume":"11","author":"Jacob","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1038\/sj.ki.5001835_bb0240","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJM198503283121304","article-title":"Catecholamine modulation of rapid potassium shifts during exercise","volume":"312","author":"Williams","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001835_bb0245","first-page":"572","article-title":"Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: absence of mediation by insulin or aldosterone","volume":"20","author":"Arrizabalaga","year":"1983","journal-title":"Proc Eur Dial Transplant Assoc"},{"key":"10.1038\/sj.ki.5001835_bb0250","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1464-5491.2001.00416.x","article-title":"Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with Type 2 diabetes mellitus","volume":"18","author":"Mehrotra","year":"2001","journal-title":"Diabet Med"},{"key":"10.1038\/sj.ki.5001835_bb0255","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1523-1755.2002.00123.x","article-title":"Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB","volume":"61","author":"Onozato","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001835_bb0260","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/jn\/132.5.897","article-title":"Dietary glutathione protects rats from diabetic nephropathy and neuropathy","volume":"132","author":"Ueno","year":"2002","journal-title":"J Nutr"},{"issue":"Suppl 1","key":"10.1038\/sj.ki.5001835_bb0265","first-page":"S127","article-title":"Carvedilol and the kidney","volume":"70","author":"Dupont","year":"1992","journal-title":"Clin Investig"},{"key":"10.1038\/sj.ki.5001835_bb0270","doi-asserted-by":"crossref","first-page":"F138","DOI":"10.1152\/ajprenal.2000.278.1.F138","article-title":"Alpha(1)-adrenoceptor subtypes in rat renal resistance vessels: in vivo and in vitro studies","volume":"278","author":"Salomonsson","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/sj.ki.5001835_bb0275","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/hc1102.105261","article-title":"Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease","volume":"105","author":"Zoccali","year":"2002","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5001835_bb0280","first-page":"85","article-title":"Beta blockers and renal function: a reappraisal","volume":"1","author":"Epstein","year":"1985","journal-title":"J Clin Hypertens"},{"key":"10.1038\/sj.ki.5001835_bb0285","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/j.1552-4604.1993.tb04677.x","article-title":"Renal effects of antihypertensive medications: an overview","volume":"33","author":"Abbott","year":"1993","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1038\/sj.ki.5001835_bb0290","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000167327","article-title":"Acute renal effects of beta-blockers","volume":"6","author":"Zech","year":"1986","journal-title":"Am J Nephrol"},{"key":"10.1038\/sj.ki.5001835_bb0295","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group","volume":"317","author":"UKPD Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.1038\/sj.ki.5001835_bb0300","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/bmj.294.6585.1443","article-title":"Effect of antihypertensive treatment on kidney function in diabetic nephropathy","volume":"294","author":"Parving","year":"1987","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1038\/sj.ki.5001835_bb0305","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes: a consensus approach","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001835_bb0310","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0272-6386(84)80083-9","article-title":"Renal perfusion is preserved during cardioselective beta-blockade with metoprolol in hypertension","volume":"3","author":"Sugino","year":"1984","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001835_bb0315","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1161\/01.CIR.65.7.1365","article-title":"Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension","volume":"65","author":"Dreslinski","year":"1982","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5001835_bb0320","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1161\/01.CIR.80.4.903","article-title":"Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients","volume":"80","author":"Van den Meiracker","year":"1989","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5001835_bb0325","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.1980.tb00501.x","article-title":"A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension","volume":"10","author":"Wilkinson","year":"1980","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/sj.ki.5001835_bb0330","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/ajh\/6.7.554","article-title":"Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension","volume":"6","author":"Ljungman","year":"1993","journal-title":"Am J Hypertens"},{"key":"10.1038\/sj.ki.5001835_bb0335","first-page":"1669","article-title":"Effect of metoprolol in patients with renal hypertension","volume":"34","author":"Yasumoto","year":"1988","journal-title":"Hinyokika Kiyo"},{"key":"10.1038\/sj.ki.5001835_bb0340","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1185\/03007999109111662","article-title":"Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients","volume":"12","author":"Tindall","year":"1991","journal-title":"Curr Med Res Opin"},{"key":"10.1038\/sj.ki.5001835_bb0345","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/clpt.1988.49","article-title":"Renal function effects of dilevalol, a nonselective beta-adrenergic blocking drug with beta-2 agonist activity","volume":"43","author":"Cook","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/sj.ki.5001835_bb0350","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00003088-198005020-00006","article-title":"The pharmacokinetics of metoprolol and its metabolites in dialysis patients","volume":"5","author":"Seiler","year":"1980","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/sj.ki.5001835_bb0355","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1046\/j.1523-1755.1999.00359.x","article-title":"Supervised atenolol therapy in the management of hemodialysis hypertension","volume":"55","author":"Agarwal","year":"1999","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001835_bb0360","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/oxfordjournals.ndt.a027840","article-title":"Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A","volume":"13","author":"Branten","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001835_bb0365","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00558387","article-title":"Pharmacokinetics of atenolol in relation to renal function","volume":"19","author":"Kirch","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1038\/sj.ki.5001835_bb0370","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00003088-198005020-00004","article-title":"Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function","volume":"5","author":"Jordo","year":"1980","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/sj.ki.5001835_bb0375","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1432-2277.2003.tb00306.x","article-title":"Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients","volume":"16","author":"Suwelack","year":"2003","journal-title":"Transpl Int"},{"key":"10.1038\/sj.ki.5001835_bb0380","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/cs1010219","article-title":"Beneficial effect of beta-adrenergic blockade on left ventricular function in haemodialysis patients","volume":"101","author":"Hara","year":"2001","journal-title":"Clin Sci (London)"},{"key":"10.1038\/sj.ki.5001835_bb0385","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bmj.304.6823.339","article-title":"Renal protective effect of enalapril in diabetic nephropathy","volume":"304","author":"Bjorck","year":"1992","journal-title":"BMJ"},{"key":"10.1038\/sj.ki.5001835_bb0390","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/bmj.309.6958.833","article-title":"Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure","volume":"309","author":"Hannedouche","year":"1994","journal-title":"BMJ"},{"key":"10.1038\/sj.ki.5001835_bb0395","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/01.HYP.21.6.786","article-title":"Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis","volume":"21","author":"Lacourciere","year":"1993","journal-title":"Hypertension"},{"key":"10.1038\/sj.ki.5001835_bb0400","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/bmj.303.6806.821","article-title":"Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease","volume":"303","author":"Apperloo","year":"1991","journal-title":"BMJ"},{"key":"10.1038\/sj.ki.5001835_bb0405","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/08037059509077575","article-title":"ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension","volume":"4","author":"Himmelmann","year":"1995","journal-title":"Blood Press"},{"key":"10.1038\/sj.ki.5001835_bb0410","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1038\/sj.ki.5001835_bb0415","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0002-9343(79)91059-3","article-title":"The long-term effect of propranolol therapy on renal function","volume":"66","author":"Bauer","year":"1979","journal-title":"Am J Med"},{"key":"10.1038\/sj.ki.5001835_bb0420","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003495-199345040-00003","article-title":"An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists","volume":"45","author":"van Zwieten","year":"1993","journal-title":"Drugs"},{"key":"10.1038\/sj.ki.5001835_bb0425","first-page":"171","article-title":"Adrenoreceptors and renal function","volume":"1","author":"Wallin","year":"1985","journal-title":"J Clin Hypertens"},{"key":"10.1038\/sj.ki.5001835_bb0430","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF01477140","article-title":"Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension","volume":"58","author":"Keusch","year":"1980","journal-title":"Klin Wochenschr"},{"key":"10.1038\/sj.ki.5001835_bb0435","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2125.1981.tb01225.x","article-title":"Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension","volume":"12","author":"Rasmussen","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/sj.ki.5001835_bb0440","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/00005344-198109000-00008","article-title":"Endocrine and metabolic effects of labetalol in man","volume":"3","author":"Barbieri","year":"1981","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1038\/sj.ki.5001835_bb0445","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF00547413","article-title":"Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension","volume":"29","author":"Ohman","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1038\/sj.ki.5001835_bb0450","first-page":"757","article-title":"Anti-hypertensive action, time of onset and effects on carbohydrate metabolism of labetalol","volume":"3","author":"Andersson","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/sj.ki.5001835_bb0455","first-page":"379","article-title":"The effects of labetalol and oxprenolol on blood lipids","volume":"60","author":"Sommers","year":"1981","journal-title":"S Afr Med J"},{"key":"10.1038\/sj.ki.5001835_bb0460","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00054642","article-title":"Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia","volume":"2","author":"Frishman","year":"1988","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1038\/sj.ki.5001835_bb0465","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/clpt.1986.207","article-title":"The disposition and dynamics of labetalol in patients on dialysis","volume":"40","author":"Halstenson","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/sj.ki.5001835_bb0470","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000065225","article-title":"Labetalol-induced hyperkalemia in renal transplant recipients","volume":"22","author":"McCauley","year":"2002","journal-title":"Am J Nephrol"},{"key":"10.1038\/sj.ki.5001835_bb0475","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000046255","article-title":"Life-threatening hyperkalemia after intravenous labetolol injection for hypertensive emergency in a hemodialysis patient","volume":"21","author":"Hamad","year":"2001","journal-title":"Am J Nephrol"},{"issue":"Suppl B","key":"10.1038\/sj.ki.5001835_bb0480","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/eurheartj\/17.suppl_B.8","article-title":"Cardiac adrenergic receptor effects of carvedilol","volume":"17","author":"Yoshikawa","year":"1996","journal-title":"Eur Heart J"},{"issue":"Suppl 11","key":"10.1038\/sj.ki.5001835_bb0485","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1097\/00005344-198706111-00024","article-title":"Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension","volume":"10","author":"Dupont","year":"1987","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1038\/sj.ki.5001835_bb0490","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.amjmed.2004.05.030","article-title":"Antioxidant and antiinflammatory effect of carvedilol in mononuclear cells of hypertensive patients","volume":"118","author":"Calo","year":"2005","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"10.1038\/sj.ki.5001835_bb0495","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1097\/00005344-199219001-00019","article-title":"Effect of long-term carvedilol therapy on renal function in essential hypertension","volume":"19","author":"Tomita","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 6","key":"10.1038\/sj.ki.5001835_bb0500","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/00003495-198800366-00022","article-title":"Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan","volume":"36","author":"Kohno","year":"1988","journal-title":"Drugs"},{"issue":"Suppl 2","key":"10.1038\/sj.ki.5001835_bb0505","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1007\/BF01409488","article-title":"Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial","volume":"38","author":"Takeda","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1038\/sj.ki.5001835_bb0510","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s002280050628","article-title":"The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency","volume":"55","author":"Gehr","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 4","key":"10.1038\/sj.ki.5001835_bb0515","first-page":"S62","article-title":"Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension","volume":"18","author":"Miki","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 1","key":"10.1038\/sj.ki.5001835_bb0520","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1097\/00005344-199219001-00020","article-title":"Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients","volume":"19","author":"Masumura","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1038\/sj.ki.5001835_bb0525","first-page":"47","article-title":"Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients","volume":"43","author":"Deetjen","year":"1995","journal-title":"Clin Nephrol"},{"key":"10.1038\/sj.ki.5001835_bb0530","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5414\/CNP57352","article-title":"Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients","volume":"57","author":"Nowicki","year":"2002","journal-title":"Clin Nephrol"},{"key":"10.1038\/sj.ki.5001835_bb0535","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/00005344-199311000-00006","article-title":"Systemic and renal hemodynamic responses to carvedilol and metoprolol in hypertensive renal transplant patients","volume":"22","author":"Leeman","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1038\/sj.ki.5001835_bb0540","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1399-0012.1997.tb01046.x","article-title":"Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients","volume":"11","author":"Kaijser","year":"1997","journal-title":"Clin Transplant"},{"key":"10.1038\/sj.ki.5001835_bb0545","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5414\/CNP58103","article-title":"Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine","volume":"58","author":"Calo","year":"2002","journal-title":"Clin Nephrol"},{"key":"10.1038\/sj.ki.5001835_bb0550","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/archinte.158.16.1743","article-title":"Chronic renal insufficiency: a diagnostic and therapeutic approach","volume":"158","author":"Rahman","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1038\/sj.ki.5001835_bb0555","first-page":"I-378","article-title":"Carvedilol improves renal hemodynamics in patients with chronic heart failure","volume":"98","author":"Abraham","year":"1998","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5001835_bb0560","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ejheart.2003.12.019","article-title":"Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (carvedilol ACE-inhibitor remodelling mild CHF evaluation)","volume":"6","author":"Komajda","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1038\/sj.ki.5001835_bb0565","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/ki.1995.132","article-title":"Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors","volume":"47","author":"Harnett","year":"1995","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001835_bb0570","first-page":"212","article-title":"Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol","volume":"12","author":"Marchi","year":"1995","journal-title":"Adv Ther"},{"key":"10.1038\/sj.ki.5001835_bb0575","first-page":"551","article-title":"Effect of antihypertensive treatment on qualitative estimates of microalbuminuria","volume":"10","author":"Agrawal","year":"1996","journal-title":"J Hum Hypertens"},{"key":"10.1038\/sj.ki.5001835_bb0580","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1742-1241.1999.tb11793.x","article-title":"Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study","volume":"53","author":"Fassbinder","year":"1999","journal-title":"Int J Clin Pract"},{"key":"10.1038\/sj.ki.5001835_bb0585","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"10.1038\/sj.ki.5001835_bb0590","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1161\/01.HYP.0000190585.54734.48","article-title":"Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes","volume":"46","author":"Bakris","year":"2005","journal-title":"Hypertension"},{"key":"10.1038\/sj.ki.5001835_bb0595","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2796.2003.01280.x","article-title":"Microalbuminuria and oxidative stress in essential hypertension","volume":"255","author":"Giner","year":"2004","journal-title":"J Intern Med"},{"key":"10.1038\/sj.ki.5001835_bb0600","doi-asserted-by":"crossref","first-page":"26734","DOI":"10.1074\/jbc.272.42.26734","article-title":"Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome","volume":"272","author":"Raats","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1038\/sj.ki.5001835_bb0605","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003495-199957040-00011","article-title":"Nebivolol in the management of essential hypertension: a review","volume":"57","author":"McNeely","year":"1999","journal-title":"Drugs"},{"issue":"Part 2","key":"10.1038\/sj.ki.5001835_bb0610","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/01.HYP.33.1.467","article-title":"Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney","volume":"33","author":"Kakoki","year":"1999","journal-title":"Hypertension"},{"key":"10.1038\/sj.ki.5001835_bb0615","first-page":"973","article-title":"Effect of nebivolol, a novel beta 1-selective adrenoceptor antagonist with vasodilating properties, on kidney function","volume":"50","author":"Greven","year":"2000","journal-title":"Arzneimittelforschung"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815518735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815518735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T03:34:39Z","timestamp":1736566479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815518735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":122,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0085253815518735"],"URL":"https:\/\/doi.org\/10.1038\/sj.ki.5001835","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}